Replies to post #763939 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Re: obecabtagene autoleuce MHRA approval.

Marketing authorisation applications (MAAs) for obe-cel in adult r/r ALL are being reviewed by the regulators in both the EU and the UK, with a submission to the European Medicines Agency (EMA) accepted in March 2024, and a submission accepted by the UK MHRA in August 2024

And that is a personalized genetic hack medicine that is more complicated than any ATL-DC.

https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-announces-fda-approval-aucatzylr

[DrHigh]

on April 2nd 2024 European Medicines Agency (EMA) has accepted the Company’s Marketing Authorization Application (MAA) for obecabtagene autoleucel (obe-cel)

Approved with FDA 11/8/2024

these guys know what they are doing. multiple irons in the fire. I guess they didn't have to worry about growing their side gig businesses